NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer

PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer. Dr. Rossomando has more than 25 years of experience as a biopharmaceutical drug developer who has successfully led teams from start-up to global biotechnology companies that have established the upstream and downstream process development of biologics and peptide molecules, including RNAi/siRNA, to advance multiple programs into clinical trials and commercialization in several therapeutic areas of neuroscience, rare diseases, and oncology.

“Tony has exceptional depth and breadth of experience in establishing the necessary development processes to support the advancement of novel biotherapeutics into clinical trials, and to approval,” said Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase. “We welcome Tony to the executive leadership team as we look to advance our first drug candidate for myotonic dystrophy, type 1 into clinical trials and continue to expand our pipeline to address genetic diseases.”

“I’m impressed with NeuBase’s PATrOL™ platform technology for genetic medicines that has demonstrated the ability to differentiate between disease-causing genetic mutations and the normal gene with single-base selectivity,” said Dr. Rossomando. “With this capability, NeuBase has the potential to develop ultra-precision genetic medicines for rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches.”

At NeuBase, Dr. Rossomando will be responsible for manufacturing and process development, analytical development, and biophysical characterization in support of FDA regulatory submissions. Prior to joining NeuBase, Dr. Rossomando was Chief Process Development Officer at Pinetree Therapeutics, where he oversaw early-stage upstream and downstream process development for bi-specific antibodies for oncology. Previous to that, he held the following positions: Vice President of Technology Operations at Anokion; Senior Director of Analytical Development at Alexion Pharmaceuticals; Vice President, Early-Stage Development at Synageva BioPharma (acquired by Alexion), Senior Director siRNA Bioprocessing at Alnylam Pharmaceuticals; Principal Scientist and Director, Protein Sciences at Biogen; and Staff Scientist at Bayer Corporation.

About NeuBase Therapeutics, Inc.
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

Use of Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. Forward-looking statements include, among others, those related to the Company’s plans to advance its first drug candidate for myotonic dystrophy, type 1 into clinical trials and continue to expand its pipeline to address genetic diseases, as well as the potential of the Company’s technologies and candidates. These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission (the “SEC”), may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the timing of the availability of data from the Company’s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:
Daniel Ferry
LifeSci Advisors, LLC
daniel@lifesciadvisors.com
+1 (617) 430-7576

NeuBase Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
+1 (858) 344-8091